The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

When bladder cancer invades nearby muscle, total removal of the organ is the standard of care A new trial finds that post-op ...

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

In its Phase 3 trial conducted in China, Ivonescimab shattered expectations, reducing the risk of disease progression or death by 49% compared to Merck's Keytruda (pembrolizumab ... Thus these two ...

Immutep (ASX:IMM) has reported that eftilagimod alpha (efti) combined with MSD's KEYTRUDA® shows high efficacy and a favourable safety profile for treating head and neck cancer. The TACTI-003 trial ...

Pediatricians Jenny Thomas and Anthony Porto both told us that parents should feel comfortable using store-brand or generic infant formulas because they contain all of the same FDA-required ...

Keytruda cuts risk of death by 20% in certain patients with gastric or gastroesophageal junction as a first-line combination ...